Side-by-side · Research reference

ARA 290vsPancragen

Side-by-side comparison across mechanism, dosage, evidence, side effects, administration, and stack synergies. Citations on every claim where available.

APhase 2HUMAN-REVIEWED17/59 cited

BAnimal-StrongHUMAN-REVIEWED23/39 cited

ARA 290

EPO-Derived Peptide · Innate Repair Receptor Agonist

4 mgDaily doseBrines 2015 Culver 2017

28 daysPhase 2 durationCulver 2017

Non-erythropoieticSafety profileBrines 2015 Liu 2014

SQ · DailyBrines 2015 Culver 2017

Pancragen

Bioregulatory Tetrapeptide · Khavinson School

50 μgPrimate doseGoncharova 2014

10 daysTreatment cycleGoncharova 2015

3+ weeksEffect persistenceGoncharova 2014

IM · 10-day cycleGoncharova 2014

01Mechanism of Action

Parameter

ARA 290

Pancragen

Primary target

Innate repair receptor (EPO receptor / CD131 heterodimer)

Pancreatic acinar and islet cell differentiation pathwaysKhavinson 2013

Pathway

EPO/CD131 → JAK2 activation → PI3K/AKT, MAPK signaling → anti-inflammatory, anti-apoptotic cascades

Transcription factor activation → Pdx1/Pax6/Pax4/Ptf1a/Foxa2/NKx2.2 upregulation → Cell differentiationKhavinson 2013

Downstream effect

Tissue protection, nerve fiber regeneration, suppression of inflammatory macrophage activation, altered T-cell differentiation (↑Treg, ↑Th2, ↓Th1)Liu 2014 Culver 2017

Enhanced pancreatic beta-cell function, normalized insulin/C-peptide dynamics, improved glucose clearanceGoncharova 2014

Feedback intact?

N/A — does not interact with hematopoietic EPO receptorLiu 2014

Yes — preserves physiological glucose-insulin response

Origin

11-amino-acid sequence from EPO helix B, engineered to eliminate hematopoietic activity while retaining tissue-protective properties

Synthetic tetrapeptide derived from pancreatic tissue extracts (Khavinson bioregulator methodology)

Antibody development

Not reported in clinical trials

—

02Dosage Protocols

Parameter

ARA 290

Pancragen

Standard dose (Phase 2)

4 mg / dayBrines 2015 Culver 2017

Sarcoidosis SFN and diabetic neuropathy trials.

—

Frequency

Once daily

Self-administered subcutaneously.

Once daily for 10 daysGoncharova 2014

Duration

28 days (Phase 2)Culver 2017

Corneal nerve improvements observed by day 28.

—

Evidence basis

Phase 2 RCTsCulver 2017 Brines 2015

64-subject sarcoidosis trial, type 2 diabetes trial.

Non-human primate RCT, in vitro cell cultureGoncharova 2015 Khavinson 2013

Route

SubcutaneousBrines 2015

IntramuscularGoncharova 2015

Timing

Any time of day

No circadian dependence reported.

—

Primate dose (rhesus macaque)

—

50 μg / animal / dayGoncharova 2014

20–25-year-old females, 10-day IM protocol.

Effective concentration (in vitro)

—

0.05 ng/mLZakutskiĭ 2006

Organotypic tissue culture, both young and aged rat explants.

Treatment cycle

—

10-day course, effects persist 3+ weeks post-withdrawalGoncharova 2014

Diabetes model

—

STZ-induced diabetes (rat)

Evaluated via metabolic markers characterizing apoptosis.

03Metabolic / Fat Loss Evidence

Parameter

ARA 290

Pancragen

Primary effect

Improved metabolic control (HbA1c, fasting glucose)Brines 2015

Secondary to neuropathy treatment; direct lipolytic effects not established.

—

HbA1c

Significant reduction vs placebo

Observed in type 2 diabetes + neuropathy trial.

—

Fasting glucose

Improved in ARA 290 group

—

Body composition

Not directly quantified

Fat loss not a primary endpoint; metabolic improvements may reflect insulin sensitivity.

—

04Side Effects & Safety

Parameter

ARA 290

Pancragen

Injection site reaction

Mild, transient

—

Hematopoiesis

None — non-erythropoietic

Distinguishes ARA 290 from native EPO.

—

Cardiovascular

No thrombotic events or hypertension reported

—

Immunogenicity

No antibody formation reported

—

Tolerability

Well-tolerated in Phase 2 trialsCulver 2017 Brines 2015

Well-tolerated in aged rhesus monkeys (n=9)Goncharova 2015

Reported adverse events

—

None documented in primate studies

Human safety data

—

No published human trials; clinical use limited to Russian gerontology protocols

Absolute Contraindications

ARA 290

·Hypersensitivity to ARA 290

Pancragen

—

Relative Contraindications

ARA 290

·Active malignancy (theoretical EPO-axis concern; not observed in trials)

Pancragen

·Active pancreatic malignancy (proliferation marker upregulation)

05Administration Protocol

Parameter

ARA 290

Pancragen

1. Preparation

Reconstitute lyophilised powder per manufacturer instructions. Use sterile technique.

Lyophilised tetrapeptide reconstituted in sterile saline or water per manufacturer protocol. Concentration not specified in literature.

2. Injection site

Subcutaneous — abdomen, thigh, or upper arm. Rotate sites to avoid lipohypertrophy.

Intramuscular injection. Primate studies used daily IM dosing for 10 consecutive days.Goncharova 2015

3. Timing

Once daily, any time of day. Self-administered in Phase 2 trials.Brines 2015

No specific timing constraints documented. Administered once daily in primate protocols.

4. Dosing

4 mg daily for 28 days (Phase 2 protocol). Duration for chronic use not established.Culver 2017

10-day treatment course. Restorative effects on pancreatic function persist for at least 3 weeks post-discontinuation.Goncharova 2014

5. Storage

Lyophilised: store at controlled room temperature. Reconstituted: refrigerate, use within specified timeframe.

—

06Stack Synergy

ARA 290

+ BPC-157

Moderate

View BPC-157 →

ARA 290 targets the innate repair receptor (EPO/CD131) for nerve regeneration and anti-inflammatory signaling, while BPC-157 promotes angiogenesis and tissue repair through distinct mechanisms (likely involving VEGF, growth hormone receptor pathways). Combined, they may address both neuroinflammation and structural tissue repair in neuropathy or injury models. No direct clinical data; mechanistic overlap in tissue protection.

ARA 290: 4 mg SQ · daily
BPC-157: 250–500 mcg SQ · daily
Frequency: Once daily, same or separate injections
Primary benefit: Nerve regeneration, pain reduction, tissue healing

Pancragen

— no documented stacks